A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction

Conditions:   Coronary Disease;   Myocardial Infarction;   Heart Diseases;   Vascular Diseases;   STEMI - ST Elevation Myocardial Infarction Intervention:   Drug: RUC-4 Compound Sponsors:   CeleCor Therapeutics;   ST. Antonius hospital Nieuwegein;   Diagram BV;   Syneos Health Not yet recruiting

Source: ClinicalTrials.gov - February 26, 2020 Category: Research Source Type: clinical trials